Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates

Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody–drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberoi, Honey K., Garralda, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
CCR Translations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306344/
https://www.ncbi.nlm.nih.gov/pubmed/34135020
http://dx.doi.org/10.1158/1078-0432.CCR-21-1353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306344/
https://www.ncbi.nlm.nih.gov/pubmed/34135020
http://dx.doi.org/10.1158/1078-0432.CCR-21-1353

Ejemplares similares